Jenny F. Seligmann, MBChB, PhD, on Colorectal Cancer: Adavosertib Compared With Active Monitoring
ESMO Congress 2021
Jenny F. Seligmann, MBChB, PhD, of the University of Leeds, discusses phase II findings that suggest adavosertib improved progression-free survival, compared with active monitoring, by inhibiting the WEE1 kinase in patients with RAS- and TP53-mutant metastatic colorectal cancer. In the trial, adavosertib’s activity tended to be even greater in left-sided tumors (Abstract 382O).
The ASCO Post Staff
Karim Fizazi, MD, PhD, of the Institut Gustave Roussy, discusses phase III results from the PEACE-1 study, which showed that androgen-deprivation therapy plus docetaxel and abiraterone provided 2.5 years of additional time without radiographic disease progression or death and 1.5 additional years of survival in men with de novo high-volume metastatic castration-sensitive prostate cancer (Abstract LBA5).
The ASCO Post Staff
Jason J. Luke, MD, of UPMC Hillman Cancer Center, discusses phase III results showing that adjuvant pembrolizumab for patients with resected stage IIB and IIC melanoma decreased the risk of disease recurrence or death by 35% compared with placebo. It was also associated with significantly prolonged recurrence-free survival (Abstract LBA3).
The ASCO Post Staff
Susana N. Banerjee, MBBS, PhD, of The Royal Marsden NHS Foundation Trust, discusses phase II results of the EORTC-1508 trial, the first study to combine an anti–PD-L1 antibody, atezolizumab, with bevacizumab and the COX1/2 inhibitor acetylsalicylic acid as treatment for patients with ovarian, fallopian tube, or primary peritoneal adenocarcinoma (Abstract LBA32).
The ASCO Post Staff
Susana N. Banerjee, MBBS, PhD, of The Royal Marsden NHS Foundation Trust, discusses phase I results that have generated interest in the combination of the RAF/MEK inhibitor VS-6766 and the FAK inhibitor defactinib for patients with recurrent low-grade serous ovarian cancer, a disease that typically has limited response to conventional chemotherapy and hormonal therapy. The data support ongoing investigation (Abstract 725MO).
The ASCO Post Staff
Robin Cornelissen, MD, PhD, of Erasmus University in Rotterdam, discusses phase II findings from the ZENITH20-4 study, which explored the question of whether poziotinib could benefit patients whose newly diagnosed non–small cell lung cancer harbors EGFR and HER2 exon 20 mutations. Potentially, this novel tyrosine kinase inhibitor may fill an unmet medical need (Abstract LBA46).
